The universal sensor array is composed of 12 fluorescently silent non-specific artificial nanoreceptors (2D-nps) for the identification and classification of five proteins, three types of breast cancer cells and a structure-switching event of a macromolecule.

In this study, we have investigated the intrinsic peroxidase-like activity of citrate-capped AuNPs (perAuxidase) and demonstrated that the nanozyme function can be multiplexed and tuned by integrating oligonucleotides on a nanoparticle surface. Systematic studies revealed that by controlling the reaction parameters, the mutiplexing effect can be delayed or advanced and further used for aptasensor applications.

Circulating oncomiRs are highly stable diagnostic, prognostic, and therapeutic tumor biomarkers, which can reflect the status of the disease and response to cancer therapy. miR-141 is an oncomiR, which is overexpressed in advanced prostate cancer patients, whereas its expression is at the normal levels in the early stages of the disease. On the other hand, miR-21 is significantly elevated in the early stage, but not in the advanced prostate cancer. Here, we have demonstrated simultaneous detection of exogenous miR-21 and miR-141 from human body fluids including blood, urine and saliva using nanographene oxide. Our system enables us to specifically and reliably detect each oncomiR at different fluorescence emission channels from a large population of RNAs extracted from body fluids. We were also able to determine the content and the ratio of the miR-21 and miR-141 in 10 different miRNA cocktails composed of various, but unknown, concentrations of both oncomiRs. A strong agreement (around 90%) between the experimental results and the actual miRNA compositions was observed. Moreover, we have demonstrated that overexpressed miR-21 or miR-141 increases the fluorescence only at their signature wavelengths of 520 and 670 nm, respectively. The approach in this study combines two emerging fields of nanographene in biomedicine and the role of circulating miRNAs in cancer. Our strategy has the potential to address the current challenges in diagnosis, prognosis and staging of prostate cancer with a non- or minimally invasive approach.